Impaired immunomodulatory ability of bone marrow mesenchymal stem cells on CD4(+) T cells in aplastic anemia.

Jianping Li,Shihong Lu,Shaoguang Yang,Wen Xing,Jianming Feng,Wenqian Li,Qinjun Zhao,Hao Wu,Meili Ge,Fengxia Ma,Hui Zhao,Bin Liu,Lei Zhang,Yizhou Zheng,Zhong Chao Han
DOI: https://doi.org/10.1016/j.rinim.2012.07.002
2012-01-01
Results in Immunology
Abstract:Aplastic anemia (AA) is a marrow failure syndrome mediated by aberrant T-cell subsets. Mesenchymal stem cells (MSCs) play an important role in maintaining immune homeostasis through modulating a variety of immune cells. However, little is known about the immunomodulation potential of bone marrow MSCs (BM-MSCs) in AA. Here, we reported that BM-MSCs from AA patients were reduced in suppressing the proliferation and clonogenic potential of CD4+ T cells and the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), which was associated with decreased prostaglandin E2 (PGE2). Meanwhile, BM-MSCs from AA patients were defective to promote CD4+CD25+FOXP3+ regulatory T cells expansion through reduced transforming growth factor-β (TGF-β). No significant difference between AA and normal BM-MSCs was observed in affecting the production of interleukins (IL)-4, IL-10 and IL-17. Our data indicate that BM-MSCs were impaired in maintaining the immune homeostasis associated with CD4+ T cells, which might aggravate the marrow failure in AA.
What problem does this paper attempt to address?